Screening Study for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/330/screening-study-for-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05058846 (https://clinicaltrials.gov/show/NCT05058846)
Prevention
Pancreatic cancer screening study for people with BRCA, ATM, or PALB2 genetic mutations
Study Contact Information:
For additional information, please contact:
Phu Lam
By phone: 415-353-8337
By email: Phu.Lam@ucsf.edu
About the Study
This study will look at how often routine MRI scans detect abnormal findings in people with genetic mutations linked to hereditary cancer, specifically BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers aim to determine how frequent there are abnormal MRI and endoscopic ultrasound (EUS) results, as well as how often there is a dignosis of high-grade pancreatic precancerous lesions and pancreatic cancer. The study will also review the rate of procedures like biopsies and surgeries among participants.
Additionally, researchers will build a biorepository, or library, by collecting saliva, blood, and tissue samples, along with imaging data and health behavior information. Finally, the study will explore participants’ knowledge, attitudes, and anxiety about pancreatic cancer screening over time. Findings may contribute to a better understanding of cancer detection and lead to improvements in screening and treatment strategies.
What the Study Involves
Participants will be assigned to one of two groups:
- Group One: includes people without a strong family history of pancreatic cancer and who have a BRCA1, BRCA2, ATM or PALB2 genetic mutation and will:
- choose to have an MRI/Magnetic Resonance Cholangiopancreatography (MRCP) and Endoscopic ultrasound (EUS) every year for 10 years, or they may opt out of the annual MRI screening.
- have the opportunity to complete brief questionnaires and provide blood, saliva, and tissue samples.
- Group Two: includes people with a strong family history of pancreatic cancer and who have a BRCA1, BRCA2, ATM or PALB2 genetic mutation and will undergo MRI/MRCP or alternating MRI/MRCP and EUS every year for 10 years.
This Study is Open To:
To participate, people 18 years or older must meet the following criteria:
- be able to read and speak English
- have had genetic testing showing a BRCA1, BRCA2, ATM, or PALB2 genetic mutation.
- do not have a strong family history of pancreatic cancer, which means not having one or more close relatives, (such as a parent, sibling, grandparent, or aunt/uncle) with pancreatic cancer.
This Study is Not Open To:
This study is not open to people under the age of 18 who:
- have been diagnosed with pancreatic cancer
- are pregnant
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.